Overview

Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

Status:
Recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of BiRd regimen combined with BCMA CAR T cell therapy in newly diagnosed multiple myeloma patients
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Collaborators:
Affiliated Hospital of Jiangnan University
Changshu Frist People's Hospital
Huai'an Second People's Hospital
Jiangsu Province Hospital of Traditional Chinese Medicine
Jiangyin People's Hospital
Jingjiang People's Hospital
Lianyungang Hospital Affiliated Bengbu Medical College
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Suzhou Municipal Hospital
The first Affiliated Hospital of Nanjing University Medical School
The First Affiliated Hospital with Nanjing Medical University
The Third People's Hospital of Kunshan
Zhangjiagang First People's Hospital
Treatments:
BB 1101
Clarithromycin
Dexamethasone
Dexamethasone acetate
Lenalidomide